The National Institute for Health and Clinical Excellence has issued Final Appraisal Determinations (FAD) for Primary Prevention and Secondary Prevention of fractures in postmenopausal women with osteoporosis.
These are the second set of FAD documents to have been published. The originals were published almost a year ago but have been the subject of several appeals.
The current guidance is still considered to be in draft form until it is published as a completed appraisal. If the advice is not subjected to further appeals then alendronate will be the first line therapy choice with alternatives reserved for cases of intolerance but only in patients who have more severe osteoporosis as measured by T score.
Action: As previously recommended, clinicians should await the finalised NICE guidance before making changes to current practice or existing treatments.